| VAC18193 / J&J |
2021-001909-77: RSV Vaccine Phase 3 study for participants aged 18 to 59 years |
|
|
| Not yet recruiting | 3 | 1113 | Europe | Ad26.RSV.preF-based Vaccine, VAC18193, Suspension for injection | Janssen Vaccines & Prevention B.V., Janssen Vaccines & Prevention B.V. | Prevention of Lower Respiratory Tract Disease Caused by The respiratory syncytial virus (RSV), Prevention of Lower Respiratory Tract Disease Caused by RSV, Diseases [C] - Virus Diseases [C02] | | | | |
NCT05242432: A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants |
|
|
| Terminated | 3 | 2192 | Japan | Ad26/protein preF RSV Vaccine, VAC18193, Placebo | Janssen Pharmaceutical K.K. | Respiratory Syncytial Virus Prevention | 03/23 | 03/23 | | |
EVERGREEN, NCT04908683: A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older |
|
|
| Completed | 3 | 25236 | Europe, Canada, US, RoW | Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF, Placebo | Janssen Vaccines & Prevention B.V. | Respiratory Syncytial Viruses, Lower Respiratory Tract Disease | 07/23 | 07/23 | | |
2020-005458-97: RSV Vaccine Phase 3 study for participants age 60 years and older |
|
|
| Not yet recruiting | 3 | 27140 | Europe | Ad26.RSV.preF-based Vaccine, VAC18193, Suspension for injection | Janssen Vaccines & Prevention B.V., Janssen Vaccines & Prevention B.V. | Prevention of Lower Respiratory Tract Disease Caused by The respiratory syncytial virus (RSV), Prevention of Lower Respiratory Tract Disease Caused by RSV, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
CYPRESS, NCT03982199: A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older |
|
|
| Terminated | 2 | 5815 | US | RSV Vaccine, Placebo | Janssen Vaccines & Prevention B.V. | Respiratory Syncytial Viruses, Respiratory Tract Diseases | 06/22 | 05/23 | | |
2022-001015-14: A Phase 1/2a Study of Various RSV preF-Based Vaccine Formulations in Adults Aged 60 Years and Older Estudio fase 1/2a de varias formulaciones de vacunas basadas en RSV.preF en adultos de 60 años en adelante. |
|
|
| Not yet recruiting | 1/2 | 1600 | Europe | Ad26.RSV.preF, RSV preF protein, Ad26.RSV-B.preF2, RSV-B preF protein, JNJ-64400141, JNJ-64213175, JNJ-86051823, JNJ-78991172, Suspension for injection, Solution for injection | Janssen Vaccines & Prevention B.V., Janssen Vaccines & Prevention B.V. | Healthy volunteer (prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV)) Voluntarios sanos (prevención de la enfermedad del tracto respiratorio inferior causada por el virus respiratorio sincitial (VRS)), Healthy volunteer (prevention of lower respiratory tract disease caused by RSV) Voluntarios sanos (prevención de la enfermedad del tracto respiratorio inferior causada por el VRS), Diseases [C] - Virus Diseases [C02] | | | | |
